Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.04, Zacks reports. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.
Dianthus Therapeutics Price Performance
Shares of NASDAQ DNTH traded up $0.49 during midday trading on Monday, reaching $20.08. 176,186 shares of the stock traded hands, compared to its average volume of 267,052. Dianthus Therapeutics has a one year low of $13.37 and a one year high of $32.27. The stock has a market capitalization of $645.09 million, a PE ratio of -8.03 and a beta of 1.48. The company's 50 day moving average is $19.83 and its 200 day moving average is $22.37.
Wall Street Analysts Forecast Growth
Several research firms have commented on DNTH. Guggenheim reissued a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $54.33.
View Our Latest Analysis on DNTH
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
